<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251381</url>
  </required_header>
  <id_info>
    <org_study_id>62202-655</org_study_id>
    <nct_id>NCT00251381</nct_id>
  </id_info>
  <brief_title>Cetuximab &amp; Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.</brief_title>
  <official_title>Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment With Cetuximab in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trial Form Support S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Trial Form Support S.L.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the 1-year rate of locoregional disease control in
      the experimental arm, using a control arm to avoid selection bias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To determine the 1-year rate of locoregional disease control in the experimental arm,
           using a control arm to avoid selection bias.

        -  To determine the 2 and 3 year rate of locoregional disease control.

        -  To evaluate the safety and toxicity of the combination of cetuximab and
           concomitant-boost accelerated radiotherapy followed by 12 weeks of complementary
           treatment with cetuximab. Both acute and chronic toxicity will be assessed.

        -  To determine specific disease-free survival, event-free survival, disease-specific
           survival and overall survival

        -  To determine acute and late toxicity

        -  To determine EGFR, p53, Ki67, and evaluate its value as a prognostic factor.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date>November 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year rate of Locoregional Disease Control in the experimental arm, deffined as complete and persistent disappearance of disease in the primary tumour and regional lymph nodes.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety of treatment will be evaluated using the Common Toxicity Criteria (CTC) of the NCI, version 3.0.; and late toxicity from radiotherapy, using RTOG/EORTC Late Radiation Morbidity Scoring Scheme.</measure>
  </secondary_outcome>
  <enrollment>90</enrollment>
  <condition>Oropharyngeal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Aged between 18 and 80, inclusive.

          -  Karnofsky functional status &gt;= 70% at the time of enrolment in study.

          -  Life expectancy of more than 3 months.

          -  Histologically confirmed diagnosis of oropharyngeal squamous cell carcinoma: base of
             tongue, vallecula, tonsil and tonsillar fossa and pillars, glossotonsillar sulcus,
             inferior surface of the soft palate, uvula and lateral and posterior oropharyngeal
             wall.

          -  Stage III or IV with no evidence of distant metastasis (IVA or IV B)

          -  Patients in medical conditions to receive a radical concomitant-boost accelerated
             radiotherapy treatment.

          -  Neutrophils &gt;= 1500/ mm3, platelet count &gt;= 100 000/ mm3 and haemoglobin &gt;= 10 g/ dL.

          -  Proper liver function: total bilirubin &lt;= 1.5 x upper limit of normal (ULN); aspartate
             aminotransferase (AST) and alanine aminotransferase (ALT) &lt;= 2.5 x ULN.

          -  Proper renal function: serum creatinine &lt;= 1.5 x ULN; if the values are &gt; 1.5 x ULN,
             creatinine clearance should be &gt;= 55 ml/min.

          -  Serum calcium within normal limits.

          -  Adequate nutritional state: weight loss &lt; 20% with respect to usual weight and serum
             albumin &gt; 35 g/l.

          -  Effective birth control method if there is possibility of conception and/or pregnancy.

          -  Availability of tumour tissue for immunohistochemical analysis of EGFR expression.

        Exclusion Criteria:

          -  Metastatic disease.

          -  Previous surgical, radiotherapy and/or chemotherapy treatment for the disease in the
             study.

          -  Other non-oropharyngeal tumour sites in the head and neck area.

          -  Other previous and/or simultaneous squamous cell carcinoma.

          -  Diagnosis of any other cancer in the previous 5 years, except properly treated
             carcinoma in situ of the uterine cervix and/or basal cell skin carcinoma.

          -  Active infection (infection requiring intravenous antibiotics), including active
             tuberculosis and diagnosed HIV.

          -  Uncontrolled hypertension defined as systolic blood pressure &gt;= 180 mm Hg and/or
             diastolic blood pressure &gt;= 130 mm Hg at rest.

          -  Pregnancy (absence of pregnancy must be confirmed with the serum-HCG test) or
             breast-feeding women.

          -  Chronic, concomitant systemic immunotherapy, or hormonal treatment for the cancer.

          -  Other concomitant anti-cancer treatments.

          -  Clinically significant coronary artery disease, history of myocardial infarction in
             the previous 12 months or high risk of out of control arrhythmia or cardiac
             insufficiency.

          -  Chronic obstructive pulmonary disease which may have required &gt; 3 hospitalisations in
             the previous 12 months.

          -  Out of control active peptic ulcer.

          -  Presence of a psychological or medical illness which might impede the patient from
             carrying out the study or giving his or her signature on the informed consent

          -  Known drug abuse (with the exception of excessive alcohol consumption)

          -  Known allergic reaction to any of the components of the treatment to be studied.

          -  Previous treatment with monoclonal antibodies or signal transduction inhibitors or
             other EGFR-targeted treatment.

          -  Any experimental treatment in the 30 days prior to enrolment in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricard Mesia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catala Oncologia: Hospital Durán y Reynals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Gomez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catala Oncologia: Hospital Durán y Reynals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaume Graupera</last_name>
    <phone>34 93 185 02 00</phone>
    <email>jaume.graupera@trialformsupport.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mar Nicolau</last_name>
    <phone>34 93 185 02 00</phone>
    <email>mar.nicolau@trialformsupport.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Tries i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08196</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireia Margelí, MD</last_name>
      <phone>3493 497 89 25</phone>
    </contact>
    <investigator>
      <last_name>Mireia Margelí, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Arellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala Oncologia: Hospital Duran y Reynals</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08097</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricard Mesia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia Lozano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico Regional de Galicia</name>
      <address>
        <city>A Coruna</city>
        <state>Coruña</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ramos, MD</last_name>
      <phone>34 981 287 499</phone>
    </contact>
    <investigator>
      <last_name>Manuel Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Martín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José L Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel De la Fuente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruth Vera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Arias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. U. de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Sta Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milva Rodriguez, MD</last_name>
      <phone>34 922 678 746</phone>
    </contact>
    <investigator>
      <last_name>Milva Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adolfo Vergez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. del Mar / H. de la Esperanza</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joan Carles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Palmira Foro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio lopez, MD</last_name>
      <phone>34 93 291 91 25</phone>
    </contact>
    <investigator>
      <last_name>Oscar Gallego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel De Vega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Josep Trueta (ICO)</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordi Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Vayreda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. G. Doctor Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Aguiar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardino Clavo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José E Alés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José A Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asunción Hervás, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Casado, MD</last_name>
      <phone>34 91 550 48 00</phone>
    </contact>
    <investigator>
      <last_name>Victoria Casado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hector Alburquerque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Escobar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Rueda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ester Villar, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ismael Herruzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.U. de Santiago</name>
      <address>
        <city>Santiago</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rafael Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mª del Carmen Porto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joaquín Casal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iñigo Nieto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2005</study_first_posted>
  <last_update_submitted>October 25, 2006</last_update_submitted>
  <last_update_submitted_qc>October 25, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2006</last_update_posted>
  <keyword>Oropharyngeal Neoplasms</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Concomitant-boost accelerated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

